louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00435149: Post-operative Mobilization for Carpal Tunnel Syndrome
Official title: Post-operative Mobilization for Carpal Tunnel
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Carpal Tunnel Syndrome
Lead sponsor: Vanderbilt University
Sponsor class: OTHER
First posted: 2007-02-14
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will investigate the effect of one week of immobilization following carpal tunnel release surgery versus no immobilization.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing open carpal tunnel release will be included in this study.
* Patients must have clinical evidence of carpal tunnel syndrome.
* Patients must have positive EMG results.
* English speaking patients only.

Patient selection factors include:

* Ability and willingness to follow instructions.
* Patients who are able and willing to return for follow-up evaluations.
* Patients of all races and genders.
* Patients who are able to follow care instructions.

Exclusion Criteria:

* Patients less than 18 years old.
* Patients who are pregnant.
* Patients unwilling or unable to comply with a rehabilitation program for carpal tunnel release who indicate difficulty or inability to return for follow-up visits prescribed by the study protocol.
* Patients who qualify for inclusion in the study, but refuse consent to participate in the study.

Primary outcomes:
measure: Function assessment questionnaire score, pain score questionnaire, and measurements will be used to determine outcome.
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt Orthopaedic Institute
state: Tennessee
Study officials:
affiliation: VUMC
name: Julie Daniels, BBA
role: STUDY_DIRECTOR
References:
Clinical trial NCT03258749: Efficiency of Twice Daily Formoterol Versus Once Daily Tiotropium in Patients With GOLD A/B COPD
Official title: Efficiency of Twice Daily Formoterol Versus Once Daily Tiotropium in Patients With GOLD A/B COPD: a Randomised, Open-label, Multicentre Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Obstructive Pulmonary Disease
Keywords: COPD
GOLD
formoterol
tiotropium
Lead sponsor: Huashan Hospital
Sponsor class: OTHER
First posted: 2017-08-23
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Chronic obstructive pulmonary disease (COPD) is a disease state characterized by persistent airflow limitation and associated with an accelerated decline in lung function, impaired quality of life, hospitalization, and increased mortality. As a major public health problem, COPD is predicted to rank as the fifth burden of diseases in the world by 2020. Thus, prevention of exacerbations is a important goal in the management of COPD. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Scientific Committee launched a joint project in 1998. Its goals were to raise awareness of COPD and to improve prevention and treatment of COPD patients around the world. In the 2017 GOLD guidelines, inhaled long-acting bronchodilators, including inhaled long-acting muscarinic antagonists (LAMAs) and inhaled long-acting beta-agonists (LABAs), are recommended for the management of all stable COPD patients. However, it is not known whether LABA or LAMA will be more effective for initial relief of symptoms in patients with GOLD A/B COPD. In this multicenter, randomized study, the investigators evaluate the efficacy of formoterol(LABA) and tiotropium(LAMA) in the treatment of patients with GOLD A/B COPD. The primary endpoint is postbronchodilator FEV1, and the secondary endpoints include the frequency of COPD exacerbation, other lung function parameters, CCQ score and mMRC/CAT score.


Eligibility criteria: Inclusion Criteria:

Clinical diagnosis of group A or group B stable COPD. Must be able to inhale Formoterol or Tiotropium.

Exclusion Criteria:

Asthma. Cystic fibrosis. Bronchiectasis. Lung cancer. Glaucoma. Tachyarrhythmia or other serious heart diseases. Prostatic hyperplasia.

Primary outcomes:
measure: postbronchodilator FEV1
timeFrame: 12 months
Secondary outcomes:
measure: the frequency of COPD exacerbation
timeFrame: 12 months
measure: other lung function parameters
timeFrame: 12 months
measure: CCQ score
timeFrame: 12 months
measure: mMRC score
timeFrame: 12 months
measure: CAT score
timeFrame: 12 months
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Huashan hospital,Fudan university
state: Shanghai
Study officials:
affiliation: Huashan Hospital
name: Shengqing Li, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04423549: Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma
Official title: Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Diffuse Large B Cell Lymphoma
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2020-06-09
Enrollment: 800
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: adults

Brief summary: The purpose of this study is to determine the predictive value of a mRNA signature and liquid biopsy in patients with Diffuse Large B cell lymphoma.


Eligibility criteria: Inclusion Criteria:

* biopsy proved Diffuse Large B cell Lymphoma
* newly diagnosed between 2000-01 and 2015-12

Exclusion Criteria:

* patients with biopsy samples unavailable

Primary outcomes:
measure: Overall survival
timeFrame: 5-years
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,
Study officials:
References:
Clinical trial NCT00688649: Nutritional Supplement Compliance Study
Official title: An Investigation of the Effects of Different Modes of Delivery of Oral Nutritional Supplements in Participants at Risk of Malnutrition - A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Undernutrition
Lead sponsor: Nutricia UK Ltd
Sponsor class: INDUSTRY
First posted: 2008-06-03
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Disease-related malnutrition is common across healthcare settings in the UK and if left untreated, may have severe consequences. One of the strategies commonly used to combat malnutrition is the use of oral nutritional supplements (ONS). However, there is uncertainty about the optimal way of delivering ONS to patients to maximize compliance and nutrient intake.

This randomised study will investigate the effect of different modes of delivery (ad libitum versus instructions on timing/serving volume) of ONS used in addition to the diet on total nutrient intake, compliance, nutritional status and outcome in participants at risk of malnutrition.

Participants will be randomised to receive one of two ONS (high energy or standard) for 4 weeks in addition to food, either taken 'Ad libitum', or according to instruction on what to take and when. The primary outcome measure is nutrient intake. Secondary outcome measures include compliance and acceptability of ONS, appetite, anthropometry, muscle strength, quality of life and gastro-intestinal tolerance.


Eligibility criteria: Inclusion Criteria:

* Male or female
* Age \> 18 years
* At risk of malnutrition (medium or high risk of malnutrition with 'Malnutrition Universal Screening Tool', 'MUST' score ≥ 1)
* Competent to provide written informed consent and able to answer questions
* No requirement for tube or parenteral feeding
* Willingness to take part in the study and to follow the study protocol

Exclusion Criteria:

* Requirement for tube or parenteral nutrition
* Participants receiving palliative care
* Participants with chronic renal disease requiring dialysis
* Participants with liver failure
* Participants that are pregnant or lactating
* Participation in other studies

Primary outcomes:
measure: Nutrient intake (energy, protein and micronutrients)
timeFrame: 4 weeks
Secondary outcomes:
measure: Compliance with ONS
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Bath
country: United Kingdom
facility: Royal United Hospital, Nutrition and Dietetics Dept
state: Wiltshire
Study officials:
affiliation: Nutricia UK
name: Lucio Fumi
role: STUDY_DIRECTOR
References:
Clinical trial NCT05278949: Re-fixating Dislocated Scleral Fixing Intra-ocular Lens
Official title: A Novel Technique of Re-fixating Dislocated Scleral Fixing Intra-ocular Lens
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intraocular Lens Complication
Keywords: Intraocular lens dislocation
Scleral re-fixation
scleral fixation
Lead sponsor: Ibinsina Modern Eye and Retina Center
Sponsor class: OTHER
First posted: 2022-03-14
Enrollment: 5
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To minimize multiple manipulations and to decrease the economical burden; here, we describe how to utilize the patient's own dislocated intraocular lens to re-fixate with the sclera.

Detailed description: When a scleral fixated intraocular lens (IOL) is displaced; routinely it is extracted and exchanged with another IOL and re-fixated to the sclera or another modality can be used. Both can carry many complications due to multiple manipulations. Nevertheless, suture and/or haptic end exposure is another expected future complication, which can range from foreign body sensation to endophthalmitis.

Here, the investigators utilized the same participant's IOL with minimum manipulations and the haptic ends buried inside scleral pockets to prevent future exposure and complications. The pocket entry is sutured with 8/0 vicryl, which is absorbable, to overcome complications.

Eligibility criteria: Inclusion Criteria:

* Dislocated primary scleral fixed IOL

Exclusion Criteria:

* Iris claw IOL
* Anterior chamber IOL

Primary outcomes:
measure: The slit-lamp examination.
timeFrame: The fourth week post-operatively.
Secondary outcomes:
measure: The visual acuity.
timeFrame: The fourth week post-operatively.
Other outcomes:
Locations:
city: Erbil
country: Iraq
facility: Ibinsina Modern eye and retina center
Study officials:
affiliation: Ibinsina Modern Eye and Retina Center
name: Omer Abdullah, M.Sc.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05419349: Novel Staging Schemes for Siewert Type II Esophagogastric Junction Adenocarcinoma: A Real-World Data Cohort Study From SEER Database
Official title: Novel Staging Schemes for Siewert Type II Esophagogastric Junction Adenocarcinoma: A Real-World Data Cohort Study From SEER Database
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Adenocarcinoma of the Esophagogastric Junction
Keywords: esophagogastric junction
total examined lymph nodes
staging
Lead sponsor: Fujian Medical University Union Hospital
Sponsor class: OTHER
First posted: 2022-06-15
Enrollment: 1819
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The data were obtained from the SEER public database. In the 18 SEER registries, the 2021 release of the public use dataset from 2004 to 2015 was queried.

Brief summary: This study have two aims, the first is to explore the optimal cutoff of TLN for Siewert type II AEG using the Surveillance, Epidemiology, and End Results (SEER) database the second is to provide a more accurate staging for Siewert type II AEG patients.


Eligibility criteria: Inclusion Criteria:

Siewert type for adenocarcinoma of the esophagogastric junction; pathologically confirmed T1-4aN0-3M0 stage after surgery after a pathological examination of the LNs.

Primary outcomes:
measure: Overall survival
timeFrame: 5-year overall survival
Secondary outcomes:
Other outcomes:
Locations:
city: Fuzhou
country: China
facility: Fujian Medical University Union Hospital
state: Fujian
Study officials:
References:
Clinical trial NCT00624949: Aortic Dimensions in Turner Syndrome
Official title: Aortic Dimensions, 24hour Ambulatory Blood Pressure and Sympathovagal Tone in Turner Syndrome. In Relation to Aortic Dilatation and Dissection.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Turner Syndrome
Keywords: Turner syndrome
aortic dimensions
blood pressure
aortic dilatation
aortic rupture
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2008-02-28
Enrollment: 102
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Recrutted from hospital clinics and through the patient organisation

Brief summary: An observational study of 102 women with Turner syndrome followed for 6 years with a two-yearly examination including ECHO, MRI of the heart and 24 ambulatory blood pressure. It has been found that besides an significantly increased risk of congenital cardiac malformations, TS have an increased risk of developing cardiac disease including the life threatening condition of aortic dilatation and rupture. The aim of the study is to describe the cardiac conditions of TS, evaluate different methods of examination and identify possible risc factors.


Eligibility criteria: Inclusion Criteria:

* Turner syndrome
* Age 18-70 years

Exclusion Criteria:

* Extreme adipositas
* Contraindications to a MRI scan
* Malignant disease

Primary outcomes:
measure: Aortic diameter at 3 well-defined levels measured by MRI and ECHO
timeFrame: 2-yearly for 6 years
Secondary outcomes:
measure: 24hour ambulatory blood pressure
timeFrame: 24h 2-yearly for 6 years
Other outcomes:
Locations:
Study officials:
References:
citation: Trolle C, Mortensen KH, Bjerre M, Hougaard DM, Cohen A, Andersen NH, Gravholt CH. Osteoprotegerin in Turner syndrome - relationship to aortic diameter. Clin Endocrinol (Oxf). 2015 Mar;82(3):397-403. doi: 10.1111/cen.12522. Epub 2014 Jul 2.
citation: Trolle C, Mortensen KH, Pedersen LN, Berglund A, Jensen HK, Andersen NH, Gravholt CH. Long QT interval in Turner syndrome--a high prevalence of LQTS gene mutations. PLoS One. 2013 Jul 25;8(7):e69614. doi: 10.1371/journal.pone.0069614. Print 2013.
Clinical trial NCT06343649: Response in Patients with Persistent Pelvic Pain to Motor Imagery Through Auditory or Visual Input. a Pilot Randomized Trial.
Official title: Response in Patients with Persistent Pelvic Pain to Explicit Motor Imagery Through Auditory or Visual Input
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pelvic Pain
Keywords: pain
pelvic pain
Lead sponsor: University of Valencia
Sponsor class: OTHER
First posted: 2024-04-02
Enrollment: 49
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to compare the response of Explicit Motor Imagery interventions in patients suffering Persistent Pelvic Pain. The main question it aims to answer is:

• Does the modality of application of Explicit Motor Imagery, either through visual or auditory stimuli, influence the response in patients suffering Persistent Pelvic Pain?

Participants will receive an online Explicit Motor Imagery program either through visual inputs or auditory inputs. They will be instructed to follow the program en register their response.

Researchers will compare visual Explicit Motor Imagery and auditory Explicit Motor Imagery to see if different inputs generate different responses in patients suffering Persistent Pelvic Pain.


Eligibility criteria: Inclusion Criteria:

* Experience persistent pain for a minimum duration of six months.
* Achieve a minimum score of six points on the Chronic Pelvic Pain Questionnaire (CPPQ), a validated instrument designed to assess the discrimination of pain.

Exclusion Criteria:

* Participants with a medically diagnosed condition that logically accounts for the presence of pain during the aforementioned six-month period

Primary outcomes:
measure: Numerical Rating Scale
timeFrame: Baseline to two weeks
measure: Pain Vigilance and Awareness Questionnaire
timeFrame: Baseline to two weeks
Secondary outcomes:
measure: Movement Imagery Questionnaire-Revised
timeFrame: Baseline
Other outcomes:
Locations:
city: Valencia
country: Spain
facility: University of Valencia
Study officials:
References:
Clinical trial NCT02027649: Detection of K14 in Bladder Cancer With a Non Invasive Technique
Official title: K14 in Urothelial Cells as a Pronostic and Diagnostic Marker in Bladder Cancer Patients Using a Non Invasive Technique.
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Bladder Cancer
Keywords: Bladder cancer
Keratin 14
Pronostic marker
Diagnostic marker
Noninvasive technique
Lead sponsor: Corporacion Parc Tauli
Sponsor class: OTHER
First posted: 2014-01-06
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Hospital patients.

Brief summary: By an invasive technique keratin 14 has been identified as a prognostic factor in bladder cancer. This study aims to analyze whether through a non-invasive technique keratin 14 can be used as a diagnostic and prognostic marker for this cancer.


Eligibility criteria: Inclusion Criteria:

* Bladder cancer

Exclusion Criteria:

* Inability to sign the informed consent

Primary outcomes:
measure: Keratin 14
timeFrame: At the time of study entry
Secondary outcomes:
Other outcomes:
Locations:
city: Sabadell
country: Spain
facility: Corporació Sanitària i Universitària Parc Taulí
state: Barcelona
Study officials:
References:
Clinical trial NCT01573949: A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)
Official title: A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes
Heart Failure
Keywords: Heart Failure
Diabetes
Pre-diabetes
Early type II diabetes
Metformin
Pharmacotherapy with metformin for prevention of DM in HF patients with pre-diabetes (pre-DM) and glycemic control in HF patients with early type II DM
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
First posted: 2012-04-10
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The Ahmanson-UCLA Cardiomyopathy Center is conducting a clinical research study that will assess the use of the medication metformin to improve quality of life, exercise capacity, and improved outcomes in heart failure patients with pre-DM or early DM (type II).

If the patient participates in this study, the patient will receive the drug metformin for approximately 3 months. During the study the patient will undergo comprehensive testing which includes blood draws and echocardiograms. The patient will also fill out a questionnaire. The patient must be 18 years old to participate.


Eligibility criteria: Inclusion Criteria:

* symptomatic HF of any etiology
* age ≥ 18 years
* fasting blood sugar equal or greater than 100 mg/dL, or pre-DM (HbA1c 5.7 - 6.4%) or early DM (HbA1c ≥ 6.5%)

Exclusion Criteria:

* current metformin therapy or other anti-diabetic therapy
* previous intolerance to metformin therapy
* renal dysfunction (Cr \>1.5 in men or \> 1.4 in women or creatinine clearance \< 60 ml/minute)
* history of lactic acidosis
* current or planned pregnancy or breast-feeding

Primary outcomes:
measure: Health-Related Quality of Life (HRQoL)
timeFrame: 3 months
Secondary outcomes:
measure: Glycated Hemoglobin (HbA1c)
timeFrame: 3 months
measure: Left Ventricular Ejection Fraction (LVEF)
timeFrame: 3 months
measure: Creatinine Level as a Measure of Renal Function
timeFrame: 3 months
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Ahmanson-UCLA Cardiomyopathy Center
state: California
Study officials:
affiliation: University of California, Los Angeles
name: Tamara Horwich, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03070249: Compassion Fatigue in ED Providers
Official title: Compassion Fatigue Among Emergency Department Healthcare Providers
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Compassion Fatigue
Keywords: Emergency Department
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2017-03-03
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population is health care providers working in the emergency department.

Brief summary: This study will assess compassion fatigue among healthcare providers in a single emergency department (ED) using the Professional Quality of Life (ProQoL) scale.


Eligibility criteria: Inclusion Criteria:

* Currently employed as a health care provider in the emergency department. All eligible individuals will be 18 years and older.

Exclusion Criteria:

* Individuals that are not currently employed in the emergency department

Primary outcomes:
measure: Assess Compassion Fatigue as precursory research
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: University of Florida
state: Florida
Study officials:
affiliation: University of Florida
name: Marie-Carmelle Elie, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03020849: Predictors of Hypofibrinogenemia in Severe Trauma
Official title: Can we Define a Clinical Score for Predicting of Hypofibrinogenemia in Severe Trauma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Severe Trauma
Keywords: hypofibrinogenemia
prediction score
severe trauma
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2017-01-13
Enrollment: 1038
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: severe trauma

Brief summary: In this retrospective and prospective study, the aim is to determine a score for predicting a fibrinogen \<1.5g/L (corresponding to European threshold of Directors recommendations of fibrinogen concentrates)


Eligibility criteria: Inclusion Criteria:

* age \> 18
* severe trauma

Exclusion Criteria:

* age \<18

Primary outcomes:
measure: rate of fibrinogen in blood sample at hospitalisation
timeFrame: day 0 (at hospitalisation)
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: HEH - Hospices Civils de Lyon
city: Pierre-Bénite
country: France
facility: CHLS, Hospices Civils de Lyon
Study officials:
References: